Browse by Series:

FDA Approval for Lutathera in Neuroendocrine Tumors

Gina Columbus
Published: Friday, Jan 26, 2018



Gina Columbus reports on the FDA approval to Lutathera (177Lutetium DOTA-octreotate) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
SELECTED
LANGUAGE
Slider Left
Slider Right


Gina Columbus reports on the FDA approval to Lutathera (177Lutetium DOTA-octreotate) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x